Intravitreal Injections in Thailand: Cost, Top Specialists & Hospitals

Intravitreal injection delivers anti-VEGF medication directly into the vitreous cavity using a very fine needle. The most common agents are ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin) — each blocking the vascular endothelial growth factor that drives abnormal vessel proliferation and leakage.

Treatment usually begins with a loading phase of three monthly injections, then transitions to a treat-and-extend protocol guided by OCT imaging. The intervals between injections are gradually lengthened as long as the retina stays dry. Some patients achieve long-term stability, while others require ongoing maintenance. Thailand's retinal centres offer all approved agents and follow the same evidence-based protocols used internationally.

Intravitreal injections in Thailand typically cost between $800 and $1,450 per injection, depending on the agent used. Bevacizumab is the most affordable option. Ranibizumab and aflibercept cost more but are purpose-designed for intravitreal use with the strongest regulatory approval. The price includes the consultation, OCT assessment, injection, and immediate post-injection monitoring.

Each session includes the retinal specialist consultation, OCT imaging assessment, the anti-VEGF medication itself, sterile injection procedure, facility fee, and immediate post-injection pressure check. For patients on ongoing treatment, package pricing for multiple injections during a single trip may be available.

The anti-VEGF agent is the main cost variable. Bevacizumab costs significantly less per injection than ranibizumab or aflibercept. For patients needing 6–12 injections per year, the choice of agent has a major impact on annual treatment cost. Clinical efficacy data supports all three agents for most indications.

Pricing varies by the complexity and scope of the procedure. Typical ranges at our partner hospitals in Thailand:

• Anti-VEGF injection (bevacizumab): $800–$950 — most affordable anti-VEGF option, widely used off-label
• Anti-VEGF injection (ranibizumab or aflibercept): $950–$1,200 — FDA-approved agents with robust clinical-trial data
• Steroid injection (dexamethasone implant): $1,100–$1,450 — slow-release steroid for inflammatory or steroid-responsive macular oedema

Exact pricing is confirmed after your consultation and treatment plan are finalised.

Intravitreal injections in Thailand cost 40–60% less per injection than in the US ($2,000–$3,200), Australia (A$1,850–A$3,050), and UK (£1,600–£2,800). Over a year of treatment involving 6–8 injections, the savings can amount to thousands of dollars.

There are no flying restrictions after intravitreal injections. You can fly the same day or the next day. The procedure does not involve gas tamponade or incisions that are affected by cabin pressure. A brief follow-up before departure confirms the eye is stable.

Virtually none. Normal activities including reading, screen use, exercise, and daily routines can resume immediately. Avoid rubbing the eye for a day or two. Swimming can resume after 24–48 hours. This is one of the least disruptive medical procedures in ophthalmology.

Each injection provides temporary disease control — typically 4–8 weeks depending on the agent and your treatment response. Anti-VEGF therapy manages the disease rather than curing it. With consistent treatment and OCT-guided scheduling, most patients maintain stable vision long-term. Some patients eventually achieve treatment-free stability, while others require ongoing maintenance.

Yes. The injection technique and sterile protocol are identical worldwide. Thailand's retinal centres follow rigorous infection-control standards including povidone-iodine antisepsis, sterile draping, and single-use instruments. Our partner ophthalmologists are fellowship-trained retinal specialists who perform high volumes of injection therapy. Infection rates at accredited centres are consistent with international benchmarks.

Anti-VEGF agents have been used intravitreally for nearly two decades, with extensive long-term safety data. The main concerns — endophthalmitis and sustained pressure elevation — are rare and well managed with proper technique and monitoring. The benefit for sight-threatening conditions consistently outweighs the small procedural risk.

Delaying or skipping injections allows the underlying disease to become active again. Fluid reaccumulates, blood vessels leak, and further vision loss can occur. Adherence to the recommended treatment schedule is important — if you cannot travel to Thailand for every injection, arrange continuation with a retinal specialist at home. Consistent treatment produces the best long-term results.

Our partner centres have dedicated retinal departments with OCT suites, fluorescein angiography, widefield imaging, and injection rooms with full sterile protocols. All three anti-VEGF agents are stocked and available for immediate use. These are active retinal treatment centres with high patient volumes.

Our partner retinal specialists manage large cohorts of anti-VEGF patients and follow evidence-based treat-and-extend protocols. They adjust treatment intervals based on OCT data, not calendar schedules, which reduces the total injection burden while maintaining disease control.

For patients who start treatment in Thailand and continue at home, our team prepares a comprehensive treatment report including OCT images, injection history, and recommended treatment interval. This allows straightforward handover to your local retinal specialist. For patients who prefer to return to Thailand for treatment, visits can be coordinated to include multiple injections during a single trip.

In wet AMD, anti-VEGF therapy prevents further vision loss in over 90% of patients and improves vision in 30–40%. In diabetic macular oedema, most patients achieve stable or improved central vision with consistent treatment. In retinal vein occlusion, anti-VEGF significantly reduces macular oedema and improves acuity. These are landmark results backed by decades of clinical trial data.

Treatment response varies by condition, severity at presentation, and treatment adherence. Patients treated early — before significant structural damage occurs — have the best outcomes. Your retinal specialist will discuss expected outcomes based on your OCT findings and diagnosis. Consistent adherence to the injection schedule is the single most important factor in long-term visual preservation.

For a single injection, 3–5 days covers the consultation, OCT assessment, injection, and follow-up. If you are starting a loading course (three monthly injections), you can schedule the first during your Thailand trip and continue the remaining two at home, or plan a longer stay to complete the series.

Each injection session includes retinal specialist consultation, OCT imaging assessment, the anti-VEGF injection, sterile procedure room, post-injection monitoring, and care coordination. Your coordinator can build a schedule that includes multiple injections during a single extended trip if preferred.

Most patients need ongoing injections for months to years. Starting in Thailand and continuing with a retinal specialist at home is a common and practical approach. Your Thai retinal surgeon provides a detailed report and treatment plan for coordinated handover. Some patients return to Thailand periodically for injection batches to benefit from lower per-injection costs.